Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Revenue (2022 - 2025)

Historic Revenue for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $10.6 million.

  • Stoke Therapeutics' Revenue rose 11724.56% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.6 million, marking a year-over-year increase of 112816.7%. This contributed to the annual value of $36.6 million for FY2024, which is 31634.4% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Revenue is $10.6 million, which was up 11724.56% from $13.8 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Revenue high stood at $158.6 million for Q1 2025, and its period low was $2.5 million during Q2 2023.
  • Over the past 4 years, Stoke Therapeutics' median Revenue value was $4.2 million (recorded in 2024), while the average stood at $16.4 million.
  • As far as peak fluctuations go, Stoke Therapeutics' Revenue crashed by 2321.26% in 2023, and later soared by 366112.43% in 2025.
  • Stoke Therapeutics' Revenue (Quarter) stood at $3.3 million in 2022, then decreased by 14.26% to $2.8 million in 2023, then soared by 707.07% to $22.6 million in 2024, then tumbled by 52.98% to $10.6 million in 2025.
  • Its last three reported values are $10.6 million in Q3 2025, $13.8 million for Q2 2025, and $158.6 million during Q1 2025.